Cargando…

Antiviral Activity of Pocapavir in a Randomized, Blinded, Placebo-Controlled Human Oral Poliovirus Vaccine Challenge Model

BACKGROUND. Immunodeficient individuals who excrete vaccine-derived polioviruses threaten polio eradication. Antivirals address this threat. METHODS. In a randomized, blinded, placebo-controlled study, adults were challenged with monovalent oral poliovirus type 1 vaccine (mOPV1) and subsequently tre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Collett, Marc S., Hincks, Jeffrey R., Benschop, Kimberley, Duizer, Erwin, van der Avoort, Harrie, Rhoden, Eric, Liu, Hongmei, Oberste, M. Steven, McKinlay, Mark A., Hartford, Marianne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5393058/ https://www.ncbi.nlm.nih.gov/pubmed/27932608 http://dx.doi.org/10.1093/infdis/jiw542

Ejemplares similares

Intestinal antibody responses to a live oral poliovirus vaccine challenge among adults previously immunized with inactivated polio vaccine in Sweden
por: Brickley, Elizabeth B, et al.
Publicado: (2019)

Randomized Controlled Clinical Trial of Bivalent Oral Poliovirus Vaccine and Inactivated Poliovirus Vaccine in Nigerian Children
por: Tagbo, Beckie N, et al.
Publicado: (2020)

Fecal Shedding of 2 Novel Live Attenuated Oral Poliovirus Type 2 Vaccine Candidates by Healthy Infants Administered Bivalent Oral Poliovirus Vaccine/Inactivated Poliovirus Vaccine: 2 Randomized Clinical Trials( )
por: Gast, Christopher, et al.
Publicado: (2021)

Neonatal Enterovirus Myocarditis With Severe Dystrophic Calcification: Novel Treatment With Pocapavir
por: Wittekind, Samuel G., et al.
Publicado: (2017)

Chronic Enteroviral Meningoencephalitis in a Patient with Good’s Syndrome Treated with Pocapavir
por: Grammatikos, Alexandros, et al.
Publicado: (2022)

Immunogenicity of Reduced-Dose Monovalent Type 2 Oral Poliovirus Vaccine in Mocuba, Mozambique
por: de Deus, Nilsa, et al.
Publicado: (2020)

Achieving High Poliovirus Antibody Seroprevalence in Areas at Risk of Vaccine-Derived Poliovirus Transmission—Niger Experience
por: Ousmane, Sani, et al.
Publicado: (2021)

Safety and Immunogenicity of Sabin Strain Inactivated Poliovirus Vaccine Compared With Salk Strain Inactivated Poliovirus Vaccine, in Different Sequential Schedules With Bivalent Oral Poliovirus Vaccine: Randomized Controlled Noninferiority Clinical Trials in China
por: Hu, Yuemei, et al.
Publicado: (2019)

A Randomized Phase 4 Study of Immunogenicity and Safety After Monovalent Oral Type 2 Sabin Poliovirus Vaccine Challenge in Children Vaccinated with Inactivated Poliovirus Vaccine in Lithuania
por: Bandyopadhyay, Ananda S, et al.
Publicado: (2020)

Circulation of Type 2 Vaccine-Derived Poliovirus in China in 2018–2019
por: Zhao, Hehe, et al.
Publicado: (2021)

Wild poliovirus type 3 (WPV3)-shedding event following detection in environmental surveillance of poliovirus essential facilities, the Netherlands, November 2022 to January 2023
por: Duizer, Erwin, et al.
Publicado: (2023)

Echovirus type 6 transmission clusters and the role of environmental surveillance in early warning, the Netherlands, 2007 to 2016
por: Monge, Susana, et al.
Publicado: (2018)

Guidance for Assessment of Poliovirus Vaccination Status and Vaccination of Children Who Have Received Poliovirus Vaccine Outside the United States
por: Marin, Mona, et al.
Publicado: (2017)

Contribution of Contact Sampling in Increasing Sensitivity of Poliovirus Detection During A Polio Outbreak—Somalia, 2013
por: Moturi, Edna, et al.
Publicado: (2016)

The Origins and Risk Factors for Serotype-2 Vaccine-Derived Poliovirus Emergences in Africa During 2016–2019
por: Gray, Elizabeth J, et al.
Publicado: (2023)

Acute Cerebellar Ataxia Associated with Poliovirus Infection
por: Curnen, Edward C., et al.
Publicado: (1961)

Assessment of poliovirus antibody seroprevalence in high risk areas for vaccine derived poliovirus transmission in Madagascar
por: Razafindratsimandresy, Richter, et al.
Publicado: (2018)

Response to a wild poliovirus type 2 (WPV2)-shedding event following accidental exposure to WPV2, the Netherlands, April 2017
por: Duizer, Erwin, et al.
Publicado: (2017)

The Duration of Intestinal Immunity After an Inactivated Poliovirus Vaccine Booster Dose in Children Immunized With Oral Vaccine: A Randomized Controlled Trial
por: John, Jacob, et al.
Publicado: (2017)

One Full or Two Fractional Doses of Inactivated Poliovirus Vaccine for Catch-up Vaccination in Older Infants: A Randomized Clinical Trial in Bangladesh( )
por: Aziz, Asma B, et al.
Publicado: (2022)

Seroprevalence of Poliovirus Antibodies in the United States Population, 2009–2010
por: Wallace, Gregory S., et al.
Publicado: (2016)

Poliovirus seroprevalence before and after interruption of poliovirus transmission in Kano State, Nigeria
por: Iliyasu, Zubairu, et al.
Publicado: (2016)

Dominant drug targets suppress the emergence of antiviral resistance
por: Tanner, Elizabeth J, et al.
Publicado: (2014)

Characterizing Environmental Surveillance Sites in Nigeria and Their Sensitivity to Detect Poliovirus and Other Enteroviruses
por: Hamisu, Abdullahi Walla, et al.
Publicado: (2020)

Safety and Efficacy of Levamisole in Loiasis: A Randomized, Placebo-controlled, Double-blind Clinical Trial
por: Campillo, Jérémy T, et al.
Publicado: (2021)

Recombination Analysis of Non-Poliovirus Members of the Enterovirus C Species: Restriction of Recombination Events to Members of the Same 3DPol Cluster
por: Brouwer, Lieke, et al.
Publicado: (2020)

Outbreak of Type 2 Vaccine-Derived Poliovirus in Nigeria: Emergence and Widespread Circulation in an Underimmunized Population
por: Wassilak, Steven, et al.
Publicado: (2011)

Influence of Enteric Infections on Response to Oral Poliovirus Vaccine: A Systematic Review and Meta-analysis
por: Parker, Edward P. K., et al.
Publicado: (2014)

FUT2 Secretor Status Is Not Associated With Oral Poliovirus Vaccine Immunogenicity in South Indian Infants
por: Parker, Edward P K, et al.
Publicado: (2019)

Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, and Clinical Effect of Danirixin in Adults With Acute, Uncomplicated Influenza
por: Roberts, Grace, et al.
Publicado: (2019)

Favipiravir Treatment of Uncomplicated Influenza in Adults: Results of Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Trials
por: Hayden, Frederick G, et al.
Publicado: (2022)

Antiretroviral Use in the CEASE Cohort Study and Implications for Direct-Acting Antiviral Therapy in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection
por: Martinello, Marianne, et al.
Publicado: (2016)

Initial Supplementary Dose of Dolutegravir in Second-Line Antiretroviral Therapy: A Noncomparative, Double-Blind, Randomized Placebo-Controlled Trial
por: Zhao, Ying, et al.
Publicado: (2023)

Duvelisib for Critically Ill Patients With Coronavirus Disease 2019: An Investigator-Initiated, Randomized, Placebo-Controlled, Double-Blind Pilot Trial
por: Goldsmith, Scott R, et al.
Publicado: (2023)

Favipiravir for Treatment of Outpatients With Asymptomatic or Uncomplicated Coronavirus Disease 2019: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial
por: Holubar, Marisa, et al.
Publicado: (2022)

Ibrutinib for Hospitalized Adults With Severe Coronavirus Disease 2019 Infection: Results of the Randomized, Double-Blind, Placebo-Controlled iNSPIRE Study
por: Coutre, Steven E, et al.
Publicado: (2022)

Preventing Vaccine-Derived Poliovirus Emergence during the Polio Endgame
por: Pons-Salort, Margarita, et al.
Publicado: (2016)

Single-Dose, Patient-Initiated Amenamevir Therapy for Recurrent Genital Herpes: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
por: Kawashima, Makoto, et al.
Publicado: (2022)

A Phase 2b, Randomized, Double-blind, Placebo-Controlled Multicenter Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of Presatovir in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus Infection of the Lower Respiratory Tract
por: Marty, Francisco M, et al.
Publicado: (2019)

Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19
por: Chen, Jun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vtshligpmvhhorpmt1s9s100jg